CA2337349A1 - Compositions ophtalmiques destinees au traitement de l'hypertension oculaire - Google Patents

Compositions ophtalmiques destinees au traitement de l'hypertension oculaire Download PDF

Info

Publication number
CA2337349A1
CA2337349A1 CA002337349A CA2337349A CA2337349A1 CA 2337349 A1 CA2337349 A1 CA 2337349A1 CA 002337349 A CA002337349 A CA 002337349A CA 2337349 A CA2337349 A CA 2337349A CA 2337349 A1 CA2337349 A1 CA 2337349A1
Authority
CA
Canada
Prior art keywords
formulation
prostaglandin
ophthalmologically acceptable
carbonic anhydrase
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002337349A
Other languages
English (en)
Inventor
Gerald S. Ponticello
Michael F. Sugrue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2337349A1 publication Critical patent/CA2337349A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des combinaisons d'une prostaglandine, d'un dérivé de prostaglandine, d'un lipide hypotenseur dérivé d'une prostaglandine ou d'un dérivé de prostaglandine ou d'un sel ophtalmologiquement acceptable de ceux-ci et d'un inhibiteur topique de l'anhydrase carbonique ou d'un sel ophtalmologiquement acceptable de celui-ci, qui sont utilisées en particulier dans le traitement de l'hypertension oculaire et du glaucome. Ces combinaisons sont caractérisées par un effet amélioré et des effets secondaires réduits.
CA002337349A 1998-07-21 1999-07-20 Compositions ophtalmiques destinees au traitement de l'hypertension oculaire Abandoned CA2337349A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11995198A 1998-07-21 1998-07-21
US09/119,951 1998-07-21
PCT/US1999/016374 WO2000004899A1 (fr) 1998-07-21 1999-07-20 Compositions ophtalmiques destinees au traitement de l'hypertension oculaire

Publications (1)

Publication Number Publication Date
CA2337349A1 true CA2337349A1 (fr) 2000-02-03

Family

ID=22387375

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002337349A Abandoned CA2337349A1 (fr) 1998-07-21 1999-07-20 Compositions ophtalmiques destinees au traitement de l'hypertension oculaire

Country Status (5)

Country Link
EP (1) EP1100491A1 (fr)
JP (1) JP2002521333A (fr)
AU (1) AU5114499A (fr)
CA (1) CA2337349A1 (fr)
WO (1) WO2000004899A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2754712B1 (fr) * 1996-10-17 1999-09-03 Merck Sharp Dohme Chibret Lab Compositions ophtalmiques
WO2000051980A1 (fr) 1999-03-05 2000-09-08 The Procter & Gamble Company Analogues de prostaglandines c16 fp selectives insaturees
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
AU2001261360A1 (en) * 2000-05-10 2001-11-20 Alcon, Inc. R-eliprodil for treating glaucoma
JP2004528369A (ja) * 2001-05-03 2004-09-16 アラーガン、インコーポレイテッド 向上した薬物動態特性を有する組成物
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
EP1797888A4 (fr) 2004-09-28 2009-12-16 Senju Pharma Co Composition ophtalmique contenant de la gomme xanthane et un acide amine
US7998942B2 (en) 2005-07-11 2011-08-16 Senju Pharamaceutical Co., Ltd. Eye drop preparation comprising xanthan gum and terpenoid
GB2423711B (en) * 2005-10-24 2007-02-14 Fortune Apex Dev Ltd Method for preparing a pharmaceutical composition with enhanced mucoadhesion
KR101381035B1 (ko) 2006-03-23 2014-04-04 센주 세이야꾸 가부시키가이샤 잔탄검 및 글루코스를 포함하는 안약 조성물
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU674038B2 (en) * 1992-10-13 1996-12-05 Alcon Laboratories, Inc. Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma

Also Published As

Publication number Publication date
JP2002521333A (ja) 2002-07-16
WO2000004899A1 (fr) 2000-02-03
AU5114499A (en) 2000-02-14
EP1100491A1 (fr) 2001-05-23

Similar Documents

Publication Publication Date Title
CA2337399A1 (fr) Compositions ophtalmiques pour le traitement de l'hypertension oculaire
CA2337349A1 (fr) Compositions ophtalmiques destinees au traitement de l'hypertension oculaire
US20120040994A1 (en) THERAPEUTIC AGENT FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDIN
EP0580268B1 (fr) Agents oculaires hypotenseurs
JP4314433B2 (ja) Ｒｈｏキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
CA2291777A1 (fr) Compositions ophtalmiques pour traitement de l'hypertension oculaire
JP4482726B2 (ja) Ｒｈｏキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
US20020094981A1 (en) Ophthalmic compositions for treating ocular hypertension
US6545045B1 (en) Prostaglandin E agonists for treatment of glaucoma
EP1267847B1 (fr) Agonistes de 5ht 2 permettant de controler la pression intra-oculaire elevee et de traiter le glaucome
CA2146006C (fr) Utilisation de derives de l'ergoline dans le traitement du glaucome
EP0509752B1 (fr) Compositions ophtalmiques contenant des combinaisons d'un inhibiteur d'anhydrase carbonique et d'un antagoniste bêta-adrénergique
US6232343B1 (en) Ophthalmic preparations
JP7346305B2 (ja) ピリジルアミノ酢酸化合物を含有する医薬製剤
US6316443B1 (en) Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist
US5405846A (en) Treatment of ocular hypertension with a synergistic combination
JP4300347B2 (ja) ブナゾシンとプロスタグランジン類からなる緑内障治療剤
US20060211700A1 (en) (R)-8,9-dichloro-2,3,4,4a-tetrahydro-1H,6H-pyrazino[1,2-a]quinoxalin-5-one for controlling IOP and treating glaucoma
US20050043412A1 (en) Remedies for glaucoma comprising bunazosin and prostaglandins
CN111479567B (zh) 包含FP激动剂和β-阻断剂的青光眼的治疗剂
US6160013A (en) 14-aza prostaglandins for the treatment of glaucoma and ocular hypertension
US6927233B1 (en) 5ht2 agonists for controlling IOP and treating glaucoma
EP1049466B1 (fr) Technique visant a accroitre la tension en oxygene du nerf optique et de la retine
WO2005023258A1 (fr) Compositions contenant des derives de benzo(g)quinoline et des derives de prostaglandine

Legal Events

Date Code Title Description
FZDE Dead